Prognostic value of lymphocyte subsets in diffuse large B cell lymphoma

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• Clinical outcomes for diffuse large B cell lymphoma (DLBCL) remain unpredictable despite identified prognostic parameters.
• Lymphocyte subpopulations are recognized as potential prognostic factors for DLBCL, but existing research has limitations due to small sample sizes and conflicting findings.

Purpose of the Study:

• To investigate the relationship between lymphocyte subsets and prognosis prediction in newly diagnosed DLBCL patients.
• To evaluate the potential of lymphocyte subsets, particularly the CD4+/CD8+ ratio, as prognostic indicators for DLBCL.

Main Methods:

• Retrospective analysis of 301 newly diagnosed DLBCL patients treated between January 2015 and December 2019.
• Correlation analysis of lymphocyte subsets with clinical features and treatment response (R-CHOP).
• Kaplan-Meier analysis to assess the association between CD4+/CD8+ ratio and progression-free survival (PFS) and overall survival (OS).

Main Results:

• Patients with more severe DLBCL exhibited lower CD19+ B cells, CD4+ T cells, and CD4+/CD8+ ratio, with higher CD8+ T cells.
• Significant associations were found between lymphocyte subsets and clinical parameters like Ann Arbor stage, IPI score, LDH, b2-MG, Ki-67, age, and neutrophils.
• A higher CD4+/CD8+ ratio at diagnosis predicted a good response to R-CHOP, longer PFS, and OS, with a low CD4+/CD8+ ratio independently associated with worse PFS.

Conclusions:

• Lymphocyte subsets, especially the CD4+/CD8+ ratio, can serve as valuable prognostic indicators for DLBCL.
• The CD4+/CD8+ ratio may be recommended for routine clinical use in predicting DLBCL prognosis.
• Further research can explore integrating lymphocyte subset analysis into standard DLBCL prognostic assessments.